Gaining Ground on Neurodegenerative Diseases
This panel discussed the rising prevalence of neurodegenerative diseases, including Alzheimer's and Parkinson's, and the importance of breakthroughs in treatment and care for these diseases. The discussion highlighted the advances in biomarker development and the significance of early detection and diagnosis. They discussed the recent validation of the first test that can detect Parkinson's disease and potential game-changing advancements like blood tests and technology in early diagnosis and treatment. The development of a drug capable of slowing the progression of Alzheimer's by Eli Lilly and Company was also discussed, along with advances in brain health programs aimed at preventing the onset of such diseases. The panelists underscored the urgency to increase funding and policy changes to support research, develop better biomarkers, and enhance access to treatments.